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Sudden cardiac arrest is the most common cause of death
among patients with end-stage kidney disease (ESKD)
maintained on hemodialysis. Here we sought to identify
dialysis-related factors associated with this increased risk in a
case–control study encompassing 43,200 patients dialyzed in
outpatient clinics of a large organization. Within this group,
we compared the clinical and dialysis-specific data of 502
patients who experienced a sudden cardiac arrest with 1632
age- and dialysis-vintage-matched controls. There were 4.5
sudden cardiac arrest events per 100,000 dialysis treatments
during the 3-year study period. These patients were
significantly more likely to have been exposed to low
potassium dialysate of less than 2meq/l. These differences
could not be explained by predialysis serum potassium
levels. There was no evidence for a beneficial effect of low
potassium dialysate even among those with higher
predialysis serum potassium levels. Other factors strongly
associated with sudden cardiac arrest by multivariable
analysis included increased ultrafiltration volumes, exposure
to low calcium dialysate, and predialysis serum creatinine
levels. These relationships persisted after adjustment for
covariates, but traditional risk factors such as history of
coronary heart disease and congestive heart failure were not
significantly influential. Hence, our study suggests that
modifications of the hemodialysis prescription may improve
the risk of sudden cardiac arrest in patients with ESKD.
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Sudden cardiac arrest (SCA) is the most common cause of death
for end-stage kidney disease (ESKD) patients treated with
hemodialysis, occurring at a rate 30 times greater than the
general population.1,2 Even if a hemodialysis patient is able to be
resuscitated after experiencing SCA, the likelihood of long-term
survival is exceedingly low.3 Therefore, one of the greatest
challenges in managing the majority of ESKD patients who
require hemodialysis therapy is how to provide the life-sustaining
treatment while minimizing the risk exposure for SCA.
An initial approach to this problem is to recognize the
profile of patients with advanced chronic kidney disease (CKD)
who are particularly vulnerable to SCA. Recent studies show
that a reduction in glomerular filtration rate alone enhances
SCA risk,4,5 but it is evident that exposure to conventional
hemodialysis augments this risk even further.6,7 Certainly, a
higher prevalence of traditional cardiac risk factors such as
advanced age, ischemic cardiomyopathy, diabetes, and pre-
existing arrhythmic heart disease is observed among patients
with CKD, but whether these factors predict SCA during a
hemodialysis treatment remains unclear.8–10 Part of the adverse
influence of hemodialysis likely results from the nonphysiologic
nature of rapid fluid and electrolyte shifts that occur during a
thrice-weekly hemodialysis schedule.6,7 In fact, epidemiologic
observations highlight that SCA risk is elevated on hemo-
dialysis treatment days and that a significant proportion of all
SCA occurs within outpatient dialysis clinics (11–18%).3,8,11
Despite this evidence, it remains unclear whether the increased
risk of SCA is because of modifiable, dialysis-specific factors or
to the exacerbation of an underlying cardiac condition.
We designed this case–control study to more clearly
identify modifiable risk factors associated with the occur-
rence of hemodialysis-associated SCA. We were particularly
interested in examining modifiable elements in the dialysis
prescription that contribute to excess SCA risk. We
hypothesized that modifiable elements of the hemodialysis
procedure such as rapid fluid and electrolyte shifts have a
larger role to peridialytic SCA risk than preexisting
traditional cardiac arrest risk factors.
RESULTS
During the observation period, 17,564,181 hemodialysis
sessions were delivered by DaVita/Gambro Healthcare.
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We identified 784 patients who experienced a documented
SCA within dialysis facilities for an event rate of 4.5 events
per 100,000 dialysis sessions, or approximately 1 in 142
patient-years. After excluding patients with missing data on
date of first hemodialysis treatment and those witho90 days
of dialysis data, we were left with a study cohort of 502
cardiac arrest cases and 1632 matched controls (Figure 1).
Table 1 compares the characteristics of SCA patients with
the matched control cohort. As planned, case and control
patients were well matched for age and dialysis vintage. There
were no differences in distribution of race or gender. SCA
case patients had a higher burden of preexisting cardiac
comorbidities including coronary artery disease (36 vs 30%,
P¼ 0.02) and congestive heart failure (40 vs 32%, Po0.001),
but there were no differences in other traditional cardiac risk
factors including history of arrhythmia, diabetes, hyperten-
sion, and hyperlipidemia. Patients who experienced SCA
were more likely to have been prescribed b-blockers (58 vs
49%, Po0.001), angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers (ACEI/ARBs; 57 vs 44%,
Po0.001; statins (36 vs 29%, P¼ 0.001), ASA (43 vs 34%,
Po0.001) and antiarrhythmic medications (25 vs 14%,
Po0.001), concordant with the observed increased
prevalence of cardiac disease among these patients. There
were no differences in proportion of patients prescribed
calcium supplements, but there was a greater use of inject-
able vitamin D (78 vs 71%, P¼ 0.004) and erythropoietin
(7310U average weekly dose vs 6201U, Po0.001) among
case patients.
Table 2 examines the last laboratory values recorded
before the event. Because most laboratory data from the
outpatient dialysis unit were drawn as a part of a scheduled
routine, laboratory data were rarely obtained on the day of
event; however, the average time between the day lab results
were obtained and the index date was between 7 and 22 days.
With the exception of hemoglobin lab results, there were no
significant differences between cases and controls in the
number of days elapsed between time all laboratory data was
obtained and the date of event (or index date). Serum
creatinine (7.0 vs 7.9, Po0.0001), albumin (3.6 vs 3.7,
P¼ 0.005), and hemoglobin (11.6 vs 11.8, P¼ 0.002) were
significantly lower among case patients, and serum bicarbo-
nate levels were slightly higher among case patients (22.0 vs
21.0, Po0.001). There were no statistically significant
differences in serum calcium, phosphorus, or parathyroid
hormone levels between the two groups.
Table 3 examines the differences in dialysis characteristics
between the two groups. There was no difference in the
dialysis dose delivered as measured by the last recorded urea
reduction ratio. Use of catheter-based vascular access was
equally prevalent between the groups. SCA patients had a
lower post-dialysis weight (67.1 vs 70.6 kg, P¼ 0.03) and a
greater proportion of their post-dialysate weight removed
through ultrafiltration (3.8 vs 3.5%, Po0.001) expressed as
an average over the 90-day study period leading up to the
event, although the difference did not reach statistical
significance when examining only the last recorded ultra-
filtration amount during the last recorded dialysis treatment
before the cardiac arrest (3.5 vs 3.4, P¼ 0.19).
Dialysate composition prescribed to patients differed
substantially between the two groups. The proportion of
patients exposed to low potassium dialysate (o2meq/l)
during the last recorded dialysis treatment was nearly double
that of matched controls (17.7 vs 9.3%, Po0.0001). We
investigated whether the higher prevalence of low potassium
dialysate could be explained by differences in the last
recorded predialysis serum potassium. As shown in Figure 2,
case patients prescribed low potassium dialysate had
significantly lower serum potassium compared with controls
(5.0 vs 5.3meq/l, P¼ 0.02). Examining the use of low
potassium dialysate (o2meq/l) during all treatments 90 days
before the cardiac arrest event yielded similar results (16.5 vs
8.7% of all treatments using low potassium dialysate,
Po0.0001). 99% of case patients prescribed low potassium
dialysate were also prescribed o2meq/l potassium baths 90
days before SCA. Examination of dialysate calcium concen-
tration showed a significantly greater exposure to low
calcium dialysate o2.5meq/l among SCA subjects (11.8 vs
6.2%, Po0.0001).
DaVita/Gambro hemodialysis population
2002–2005: N =43,200
Confirmed peridialytic
cardiac arrest: N =784
Excluded*
N=55
Cardiac arrest (cases)
N =729
Matched controls
N =2163
Exclude patients
with <90-day
dialysis data
Case cohort
N =502
Control cohort
N =1632
Figure 1 | Study flow diagram describing selection of case and
control cohorts. *Exclusion criteria include missing data on age
and dialysis vintage in accordance with our prespecified control
matching strategy.
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We constructed a multivariable logistic regression model
incorporating all variables that were significantly associated
with SCA in unadjusted analyses or variables clinically
suspected to be associated with risk of SCA. Table 4 outlines
factors that remained statistically associated with SCA in the
adjusted model, with factors listed in order of predictive
influence (based on w2-values) in the overall model. The
magnitude of the association between low potassium
dialysateo2meq/l and SCAwas strengthened in the adjusted
model, with a greater than twofold increase in the risk of
SCA (adjusted odds ratio (aOR)¼ 2.06, CI 1.48–2.86). Low
dialysate calcium o2.5meq/l also remained associated with
SCA in the adjusted model (aOR¼ 1.88, CI 1.28–2.76).
Higher predialysis serum creatinine was protective with a
15% reduction in SCA risk with every 1mg/dl increase in
creatinine over 6.5 (aOR¼ 0.85, CI 0.79–0.91). Lower
hemoglobin values (aOR¼ 1.11 per 1mg/dl decrease) and
higher serum bicarbonate (aOR¼ 1.03 per 1meq/l increase)
were associated with increased risk, but serum phosphorus
did not have an association in the adjusted model.
Prescription for antiarrhythmic medications (aOR¼ 1.68),
ACEI/ARB (aOR¼ 1.33), and activated vitamin D
(aOR¼ 1.39) were independently associated with SCA, but
there was no significant relationship between cardiovascular
medications including aspirin, b-blockers and statins and
outcome in the adjusted model. In addition, traditional
cardiac risk factors including history of CHF, diabetes, CAD,
and hyperlipidemia were not significantly associated with an
increased risk of SCA in the adjusted model. Internal
validation of model covariates was performed with the
bootstrapping procedure, by using 200 samples with
replacement. Parameter estimates and 95% CIs were
validated for all model covariates.
Figure 3 illustrates the unadjusted V-shaped relationship
between predialysis serum potassium and risk of SCA
illustrating the hazard associated with both hypo- and
hyperkalemia. This relationship persisted after adjustment,
with a 49% increase in risk with each 1meq/l decrease in
Table 1 | Baseline clinical characteristics of the case and control cohorts
Case Control Total P-value
Number 502 1632 2134
Median age (IQR) 65 (55–75) 66 (56–75) 66 (56–75) 0.4469
Male (%) 51.4 52.5 52.2 0.6786
Caucasian (%) 46.6 42.5 43.4 0.4240
Median dialysis vintage, years (IQR) 2.85 (1.5–5.1) 2.71 (0.9–5.3) 2.75 (1.0–5.3) 0.1638
Coronary artery disease (%) 36.1 30.3 31.6 0.0148
History of congestive heart failure (%) 39.8 31.7 33.7 0.0008
History of arrhythmia (%) 13.6 11.8 12.2 0.3037
Hypertensive (%) 87.1 87.4 87.4 0.8196
Diabetic (%) 57.4 53.9 54.7 0.1671
Hyperlipidemia (%) 8.2 6.4 6.8 0.1623
Tobacco use (%) 2.6 3.7 3.5 0.2189
Peripheral vascular disease (%) 20.5 18.9 19.3 0.4136
Cerebrovascular disease (%) 13.0 10.8 11.3 0.1804
Medications prescribed at time of event
Aspirin (%) 42.6 34.4 36.4 o0.0001
Statin (%) 36.3 28.5 30.4 0.0010
b-Blockers (%) 58.0 49.4 51.4 0.0008
ACEI/ARB (%) 57.4 44.4 47.5 o0.0001
Antiarrhythmic medications (%) 24.7 13.9 16.5 o0.0001
Calcium channel blockers (%) 48.2 44.7 45.5 0.1640
Injectable vitamin D (%) 77.7 71.2 72.7 0.0041
Oral calcium (%) 63.8 59.3 60.4 0.0758
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; IQR, interquartile range.
Table 2 | Laboratory data recorded before clinical event (SCA) or index date (controls)
Case Control Total P-value
Predialysis serum potassium (meq/l) 4.6 (4.1, 5.2) 4.7 (4.2, 5.3) 4.7 (4.2, 5.3) 0.0562
Calcium (mg/dl) 9.3 (8.8, 9.8) 9.2 (8.6, 9.8) 9.2 (8.7, 9.8) 0.0734
Phosphorus (mg/dl) 5.1 (4.1, 6.3) 5.1 (4.2, 6.3) 5.1 (4.1, 6.3) 0.4280
Parathyroid hormone, intact (pg/ml) 218 (109, 397) 223 (118, 395) 222 (115, 396) 0.7498
Albumin (mg/dl) 3.6 (3.3, 3.9) 3.7 (3.4, 4.0) 3.7 (3.4, 4.0) 0.0048
Hemoglobin (g/dl) 11.6 (10.8, 12.4) 11.8 (10.9, 12.6) 11.8 (10.9, 12.6) 0.0017
Creatinine (mg/dl) 7.0 (5.5, 8.9) 7.9 (5.9, 10.1) 7.6 (5.8, 9.8) o0.0001
Bicarbonate (meq/l) 22 (19, 25) 21 (18, 24) 22 (19, 24) 0.0003
Abbreviation: SCA, sudden cardiac arrest.
Median values and interquartile ranges are reported.
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serum potassium below 5.1meq/l, and a 38% increase in risk
with each 1meq/l increase over 5.1meq/l. Given this
relationship, we postulated that the detrimental effect of
low dialysate potassium might not be constant across the
continuum of predialysis serum potassium. To examine this
hypothesis, we looked for an interaction between serum and
dialysate potassium levels in the adjusted model. The
interaction term was significant (P¼ 0.026). Figure 4 illus-
trates this interaction. For predialysis serum potassium levels
less than 5meq/l, the difference in risk between those treated
with low (o2meq/l) compared with high (X2meq/l)
potassium dialysate increases as serum potassium decreases.
Among subjects with higher predialysis serum potassium
levels (above 5meq/l), there was no indication of a significant
difference in risk according to level of potassium dialysate.
Therefore, we did not find any evidence of benefit for a low
potassium dialysate (o2meq/l) at any value of predialysis
serum potassium.
DISCUSSION
It is well recognized that patients with ESKD who require
hemodialysis carry a high burden of cardiac risk. Unfor-
tunately, a major manifestation of cardiac disease in patients
with ESKD is SCA, a frequently catastrophic event that occurs
without warning. If a hemodialysis patient experiences a
SCA, the likelihood of long-term survival is bleak. We
previously reported that in approximately 800 patients who
experienced an SCA while observed in outpatient hemodia-
lysis clinics, the 30-day survival rate was only 19% and the
1-year survival rate was only 9%.3,12 It is not known if a
distinct intervention, either as an entirely new treatment or as
a modification of an ongoing therapy, will reduce the cardiac
risk in patients with ESKD who are treated with hemodia-
lysis. Previous observations have explored the nature of
exposures that occur during the dialysis procedure that may
increase the likelihood of having SCA. Karnik et al.8 observed
that hemodialysis patients who experienced SCA were more
likely to be dialyzed with a low dialysate potassium
concentration and to have catheter-based vascular access
compared a nonselected national cohort of ESKD patients.
Kovesdy et al.13 described an elevated risk of all-cause
mortality in hemodialysis patients with an elevated serum
potassium if they were treated with a dialysate potassium
concentration that exceeded 3.0meq/l. However, these
observations may be subject to bias due to limited specificity
of the clinical end point and to the lack of a carefully selected
control group.
In this study, we identified the risk profile of SCA patients
by comparing hemodialysis patients who experienced a
peridialytic SCA with matched control patients. We placed
a high priority on identifying particular aspects of the dialysis
procedure that could be modified, and the principal findings
are as follows. First, we did not observe strong relationships
between traditional cardiac arrest risk factors such as
congestive heart failure, coronary heart disease, and a
preexisting history of cardiac arrhythmia and the occurrence
of peridialytic SCA. Second, we found that the composition
of dialysate, specifically exposure to low potassium or to low
calcium dialysate concentration, was strongly influential in
predicting SCA risk. These relationships persisted even after
adjusting for preexisting cardiac comorbidities and predia-
lysis serum electrolyte levels. Even though we observed an
increasing risk of SCA among patients with predialysis serum
potassium levels above 5.0meq/l, we did not find any
advantage of using low potassium dialysate o2meq/l at
any level of serum potassium. Third, we found that
ultrafiltration of consistently large volumes during hemodia-
lysis was an important risk factor for peridialytic cardiac
arrest. Fourth, we found that lower serum creatinine was
a strong predictor SCA. Finally, we found significant
Table 3 | Dialysis characteristics of the study cohorts
Case Control Total P-value
Measured urea reduction ratio, median (IQR) 0.72 (0.67–0.76) 0.72 (0.67–0.76) 0.72 (0.67–0.76) 0.9072
Indwelling dialysis catheter 33.5 32.8 33.0 0.7660
Last recorded post-dialysis weight in kg (IQR) 67.1 (56.7–81.6) 70.6 (59.5–82.8) 70.1 (59.1–82.6) 0.0250
Percent post-dialysis weight removed during
treatment (mean over 90 days) (IQR)
3.8 (2.9–4.8) 3.5 (2.6–4.4) 3.6 (2.7–4.5) 0.0002
Dialysate potassium concentration, last recorded treatment, meq/l (%)a o0.0001
1 17.7 9.3 11.4
2 67.7 68.6 68.4
3 13.8 20.8 19.1
4 0.8 1.3 1.2
Dialysate calcium concentration, last recorded treatment, meq/l (%)b 0.0001
1 0.8 0.5 0.6
2 11.0 5.7 7.0
2.5 74.7 74.6 74.6
3 12.4 15.9 15.0
3.5 1.2 3.3 2.7
Abbreviation: IQR, interquartile range.
aDialysate categories of 1, 2, 3, and 4meq/l also include 1.5, 2.5, 3.5 and 4.5meq/l.
bDialysate categories of 1 and 3.5 also include 1.5 and 4meq/l.
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relationships between oral and injectable medications and
SCA. Taken together, these observations suggest that
modifications of the hemodialysis procedure may signifi-
cantly improve the risk of patients with ESKD.
Patients in the general population who experience a
cardiac arrest often have underlying structural heart disease,
most commonly ischemic cardiomyopathy with diminished
left ventricular ejection fraction. Therefore, traditional SCA
risk factors often correspond to identified risk factors
for atherosclerotic heart disease.14 A large proportion of
patients with CKD have coronary artery disease, whether it
is clinically evident at the time of dialysis initiation.15
A diminished left ventricular ejection fraction in patients
with ESKD also enhances the risk of SCA.16 However, in this
study we found that traditional SCA risk factors such as
preexisting coronary artery disease, congestive heart failure
hyperlipidemia, diabetes, and hypertension did not predict
SCA risk in the adjusted multivariable model. This is similar
to the findings of other investigators9 and underscores
the notion that in contrast to the general population,
atherosclerotic ischemic heart disease may not be the
predominant pathway leading to SCA among ESRD patients.
Therefore, traditional SCA prevention strategies aimed at
conventional cardiovascular risk factor reduction may not
prove beneficial among ESRD patients, and novel therapies
tailored to the unique risk profile of at-risk ESRD patients
should be developed and tested.
Other forms of cardiomyopathy are common in patients
with ESKD. Left ventricular hypertrophy is present in 25–40%
of patients who initiate dialysis17 and the presence of
left ventricular hypertrophy has been associated with an
increased risk of SCA in hemodialysis.18 At an ultrastructural
level, the presence of myocardial fibrosis can impair
ventricular conduction and predispose to ventricular ar-
rhythmias.6 Perhaps as a novel manifestation of ‘uremic
cardiomyopathy,’ a significant fraction of patients with ESKD
show an enhancement pattern on cardiac magnetic resonance
imaging that is consistent with diffuse myocardial fibrosis.19
Some have suggested that factors related to abnormal mineral
metabolism or elevation of circulating aldosterone promote
myocardial fibrosis and SCA risk in CKD.20–22 Thus, it is
evident that in many patients with advanced CKD, abnormal
myocardial structure alone may raise the baseline risk of
having from a fatal arrhythmia.
However, even among patients with significant structural
heart disease, an adverse transient condition or ‘trigger’ is
usually required for a malignant arrhythmia to occur.14 One
of the most striking observations from this and previous
studies is the strong temporal relationship between SCA and
the hemodialysis procedure itself,7 suggesting that dialysis
treatment-related issues are important in the genesis of SCA.
Elevations in circulating concentrations of catecholamines
known to occur during dialysis may trigger malignant
arrhythmias.23 It has been suggested by previous studies that
rapid removal of serum electrolytes and extracellular fluid
during hemodialysis may be the mechanism by which
hemodialysis acts as a triggering event for SCA, and this
hypothesis has been more fully explored in the present study.
This study highlights the clinical quandary that is posed
by dialysis patients with disordered potassium homeostasis.
Predialysis hyperkalemia and hypokalemia are associated
with higher all-cause mortality in hemodialysis patients,13,24
but to the best of our knowledge, this is the first study to link
extremes of predialysis serum potassium specifically to risk of
SCA. The magnitude of risk associated with dyskalemia is
substantial, but the observed influence is not completely
surprising. Serum potassium has an established role in
maintaining resting cell membrane potential, neuromuscular
excitability, and cardiac pacemaker function.25 In patients
with ESKD, hyperkalemia develops as a result of net positive
potassium balance, and hypokalemia can result from poor
dietary intake and extrarenal losses including excessive
potassium removal on dialysis. Because hyperkalemia is
encountered most frequently in ESKD patients, intermittent
hemodialysis restores potassium balance by removing
potassium rapidly using dialysate baths with lower potassium
8
7
6
5
4
3
2
25
20
15
10
5
0
Case Control
Case Control
P = 0.02
a
b
La
st
 re
co
rd
ed
 p
ot
as
siu
m
 (m
eq
/l)
 
Us
in
g 
di
al
ys
at
e 
po
ta
ss
iu
m
 <
2
m
e
q/
l d
ur
in
g 
la
st
 tr
ea
tm
en
t (%
) P<0.001
Figure 2 | Last recorded predialysis serum potassium and
dialysate potassium concentration of case and control
cohorts. (a) Last recorded serum potassium for case and control
patients who were prescribed dialysate potassium o2meq/l
during last treatment. (b) Proportion of all case and control
patients who were prescribed dialysate potassium o2meq/l
during last treatment.
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levels. However, we found that use of a potassium dialysate
o2meq/l was associated with increased risk of SCA. The
greatest incremental risk of low dialysate potassium was
among patients with predialysis serum potassium o5.1.
These findings underscore the potential detrimental effects of
aggressive potassium removal in patients who have normal or
near-normal predialysis serum potassium levels given the risk
of inadvertent hypokalemia. Despite having a median
potassium level of 5.0meq/l, approximately 20% of case
patients were prescribed low potassium baths with concen-
trations o2meq/l, and 70% of these patients were also
prescribed o2meq/l potassium baths 90 days before SCA.
These observations are similar to a previous report published
nearly a decade ago, which also observed prevalent use of low
potassium dialysate among patients who experienced cardiac
arrest in dialysis units (17.1% of cardiac arrest patients
compared with 8.8% in a comparator population cohort).8
Despite these previous findings, our study suggests that low
potassium dialysate continues to be used routinely in US
hemodialysis clinics, perhaps even with increasing prevalence
(11.3% of controls). Our study again emphasizes the
importance of regular review of serum potassium levels to
avoid low potassium dialysate among patients who have
predialysis serum potassium levels in the normal range.
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Figure 4 |Probability of sudden cardiac arrest (SCA) by dialysate
potassium concentration (X2meq/l, black line; o2meq/l, red
line) and last recorded serum potassium. Dashed lines represent
95% confidence intervals. Difference in risk is greatest for lower
levels of serum potassium, and the risk difference decreases as
serum potassium increases. No significant advantage of low
potassium dialysate is observed at any level of serum potassium.
Table 4 | Adjusted OR of SCA by clinical characteristic
Variable Adjusted odds ratio 95% Confidence interval Wald v2-test P-value
Last recorded creatinine value 22.9 o.0001
OR per 1U increase up to 6.5mg/dl 1.01 0.89, 1.15
OR per 1U increase starting at 6.5mg/dl 0.85 0.79, 0.91
Dialysate K o2 on last visit 2.06 1.48, 2.86 18.5 o.0001
Predialysis serum potassium 15.0 0.0006
OR per 1meq/l decrease below 5.1meq/l 1.55 1.23,1.96
OR per 1meq/l increase above 5.1meq/l 1.46 1.08,1.98
Antiarrhythmic prescription 1.68 1.26, 2.23 12.7 0.0004
Dialysate Ca o2.5 on last visit 1.88 1.28, 2.76 10.4 0.0012
EPO dose (weekly mean) (OR per 1000) 1.020 1.007, 1.033 9.4 0.0022
Percent volume removed (mean over 90 days) 1.11 1.02, 1.20 6.5 0.0108
ACEI/ARB prescription 1.33 1.06, 1.66 5.9 0.0151
Last recorded hemoglobin (OR per 1 g/dl increase) 0.90 0.83, 0.98 5.7 0.0172
Vitamin D use 1.39 1.06, 1.82 5.5 0.0188
Serum bicarbonate (OR per 1meq/l increase) 1.030 1.000, 1.060 3.9 0.0478
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; EPO, erythropoietin; OR, odds ratio.
Logistic regression model adjusted for gender, race, history of congestive heart failure, diabetes, hypertension, coronary heart disease, hyperlipidemia, history of arrhythmia,
medication use (aspirin, b-blockers, statins, last recorded albumin, phosphorus, last recorded urea reduction ratio, catheter use). Overall model c-statistic 0.71. Parameter
estimates and 95% CIs were validated for all model covariates using the bootstrapping procedure.
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Figure 3 | Sudden cardiac arrest (SCA) probability plotted as a
continuum of last recorded predialysis serum potassium in meq/l
(unadjusted). Dashed lines represent 95% confidence intervals.
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The challenge of managing hyperkalemia may explain the
prevalence of low potassium dialysate use in US hemodialysis
clinics despite previous associations with adverse outcomes.
Indeed, we found that every 1meq/l increment in predialysis
serum potassium concentration45.1meq/l conferred a 46%
increased risk of SCA; however, our data suggest that
management of hyperkalemic patients with low potassium
dialysateo2meq/l did not produce any significant reduction
in SCA risk. This is consistent with the findings of Kovesdy
et al.,13 who found no association between low potassium
dialysate and all-cause mortality among patients with
predialysis serum potassium 45.0; however, they noted an
increased mortality of hyperkalemic patients who were
dialyzed using high concentrations baths 43meq/l, suggest-
ing that insufficient potassium removal on dialysis may also
be a contributor to premature death. We found that the use
of low potassium dialysate o2meq/l was associated with an
increased risk of SCA even among subjects with a predialysis
serum potassium between 5.0 and 6.0 (OR 1.9, 95% CI
1.3–2.8), but no significant risk or benefit was observed
among patients with predialysis potassium 46.0 (OR¼ 0.9,
95% CI 0.4–1.8). However, as we found an increased risk of
low potassium dialysate among patients with predialysis
serum potassium p6meq/l and no significant benefit even
among patients with serum potassium 46meq/l, we cannot
recommend the routine fixed assignment of dialysate with
potassium concentrationso2meq/l in the outpatient setting.
Whether the principal risk of low potassium dialysate in
hyperkalemic patients results from hypokalemia induced by
aggressive potassium removal or by rapid changes in
potassium concentrations produced by large serum–dialysate
potassium gradients cannot be determined from our data.
The importance of the serum–dialysate potassium gradient
was examined experimentally in a previous study that
tested the effect of a variable dialysate potassium profiling
technique on the occurrence of premature ventri-
cular contractions in 30 hemodialysis patients.26 Among a
subgroup of especially arrhythmia-prone subjects, the
investigators showed a threefold decrease in intradialytic
premature ventricular contractions in subjects whose
dialysate potassium concentration was reduced gradually
through the course of the treatment. Whether this technique
and other dialytic techniques that incorporate more
gradual removal of serum potassium (such nocturnal and
daily hemodialysis) can ultimately reduce the incidence of
fatal arrhythmias is unknown, and the ability to vary
dialysate potassium concentration during a hemodialysis
treatment is not routinely available in clinical practice.
Alternatively, more frequent predialysis serum potassium
monitoring with appropriate adjustments in dialysate
composition or oral administration of potassium-binding
resins are other strategies that should be explored to reduce
the high incidence of SCA.
We found that the quantity of fluid removed (ultrafiltra-
tion) on dialysis, expressed as percent of total body weight
removed, was independently predictive of SCA risk. Greater
quantity of fluid removal over relatively short periods of time
on dialysis can result in intradialytic hypotension and
possible myocardial injury.27 A recent observational study
reported a significant association between increased ultra-
filtration volumes and the occurrence of intradialytic cardiac
regional wall motion abnormalities,28 a marker of myocardial
stunning and injury. Additional studies have found associa-
tions between ultrafiltration rate and all-cause mortality.29
The ultrafiltration target is largely determined empirically,
considering the patient’s interdialytic weight gain, symptoms,
and physical examination findings. Thus, available modifi-
cations to a conventional hemodialysis prescription that
will reduce ultrafiltration targets are limited. However, our
findings may provide additional impetus to diminish
treatment-related volume removal by using frequent daily
or nocturnal HD therapies, which have been shown to
improve both intradialytic hemodynamics and plasma
concentrations of biochemical markers of myocardial
injury.30 Although data continue to emerge regarding these
modalities, our findings emphasize the need to counsel
patients regarding the hazards of excessive intradialytic
weight gain.
We also found a strong link between low predialysis serum
creatinine and risk of peridialytic SCA. Studies have
consistently reported an increased mortality in patients with
lower levels of serum creatinine than expected from the
intensity of dialysis, and the presence of low serum creatinine
often correlates with other markers of malnutrition (such as
serum albumin and body mass index) and markers of
increased inflammation.24,31,32 A secondary analysis of the
Choices for Health Outcomes in Caring for ESRD (CHOICE)
study highlighted the role of inflammation and malnutrition
in SCA risk among dialysis patients.9 Higher levels of serum
C-reactive protein, IL-6, and lower serum albumin were
independently predictive of sudden cardiac death risk.
Approaches to modify these parameters have been met with
limited success, and whether improvement in these para-
meters will result in improved outcomes remains unproven.
Nevertheless, one potential use of our findings is that high-
risk patients can be identified in hemodialysis populations,
and these groups of patients can be targeted for treatment
with novel therapies. Although we did not observe a
reduction in SCA risk among patients prescribed b-blockers
in our analysis, b-blockers such as carvedilol have shown
promise in reducing cardiovascular mortality33 and survival
after SCA3 among dialysis patients. In addition, a recent
randomized trial suggested that nicorandil, a nitrate and
ATP-sensitive potassium channel opener, improved cardio-
vascular outcomes in hemodialysis patients who underwent
coronary revascularization.34 More controversial is the
implantation of a device such as a cardioverter defibrillator
that has been associated with improved survival among
hemodialysis patients,35 but a recent analysis suggested that
despite having these devices, patients with ESKD who receive
dialysis have a 2.7-fold higher mortality compared with those
patients who do not receive hemodialysis.36
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We examined oral and injectable medications prescribed
to patients at the time of SCA and found that prescriptions
for antiarrhythmic medications, ACEI/ARBs, vitamin D,
and increasing doses of erythropoietin were independently
associated with SCA risk. As we cannot fully exclude the
possibility of indication bias associated with these medica-
tions, the implications of these findings are uncertain. The
association of SCA with the use of antiarrhythmic medica-
tions may reflect true harm (as has been observed in other
populations37) or it may simply reflect confounding by
indication, even though we adjusted for documented history
of arrhythmic disease. Similarly, the association with ACEI/
ARBs may reflect unmeasured confounding from underlying
disease (such as an increased prevalence of ischemic heart
disease), although the relationship persisted after adjustment
for preexisting CAD and we did not observe any association
with other common medications for CAD such as aspirin,
b-blockers, calcium channel blockers or statins. Alternatively,
ACEI/ARBs may increase SCA among dialysis patients
through hyperkalemia, which has been observed among
chronic hemodialysis patients with and without residual
renal function using ACEI/ARBs.38 However, in our analysis,
we did not observe a significant interaction between ACEI/
ARBs prescriptions and serum potassium levels (P¼ 0.3). We
found that prescription for injectable vitamin D and vitamin
D analogues was associated with an increased risk of SCA.
This differs from retrospective reports that describe an
association of vitamin D analogues with survival benefit.39
Doses of vitamin D administered on dialysis frequently result
in hypercalcemia and an elevated calcium-phosphate pro-
duct, which can in turn accelerate vascular calcification, a
possible pathophysiologic pathway for premature cardiovas-
cular death.22 Vitamin D use has also been associated with
vascular calcification independent of its effects on serum
calcium and phosphorus.40 Finally, we observed an incre-
mental risk associated with higher doses of weekly erythro-
poietin. In a secondary analysis of the Correction of
Hemoglobin and Outcomes in Renal Insufficiency study,
high-dose epoetin-a was associated with a significant
increased hazard of cardiovascular events.41 This finding
may also be explained by a higher incidence of erythropoietin
resistance among patients who experience SCA, a known
indicator for overall mortality and morbidity.42
Our study has several limitations. First, we only examined
patients who had experienced witnessed peridialytic SCA
within dialysis centers. Although this limits the general-
izability of our findings, we did this to increase the reliability
of our findings compared with similar studies relying on
external reporting of the cause of death, which may
misrepresent the true incidence of SCA.43,44 In addition, as
14% of all SCA in hemodialysis patients occurs within
dialysis clinics and an additional 19% of all SCA occur in the
period immediately following outpatient dialysis treatment,
our findings may not extend to patients who experience SCA
outside hemodialysis clinics at a time remote from the
hemodialysis procedure. We also excluded patients who
experienced SCA within 90 days of dialysis initiation. We did
this to exclude non-ESKD patients who may have received
hemodialysis temporarily due to reversible kidney injury and
to have sufficient data to analyze factors leading up to the
SCA event. Therefore, our findings may not apply to ESKD
patients who experience SCA within 90 days of dialysis
initiation. Second, as with all observational data, any
relationships described can only be ascribed to be associa-
tions and causality cannot be proven. We acknowledge that
relevant exposures and significant events such as hospitaliza-
tions were not captured and may be important in determin-
ing SCA risk. Specifically, we did not have access to
laboratory data obtained outside the dialysis clinic; and it is
possible that relationships between dialysate and serum
potassium concentrations and SCA risk might have been
influenced by laboratory data obtained elsewhere. We also
acknowledge that significant underreporting and information
bias may exist with comorbidity reporting contained in
electronic medical records, and that the time point for entry
of a diagnosis does not always coincide with reporting of the
diagnosis. This limitation exists despite attempts to minimize
the influence of unmeasured confounders by using multiple
comprehensive sources of data and comorbidity reporting.
Finally, misclassification bias might have resulted from the
inclusion of patients who could have experienced an out of
clinic SCA in the control group, but substantial misclassifica-
tion would be expected to bias toward the null.
In summary, we found that modifiable elements of the
hemodialysis prescription are crucial in determining peri-
dialytic SCA risk and that these factors were more influential
than traditional SCA risk factors. More focused attention to
hemodialysis factors such as the management of dyskalemia
and volume homeostasis may significantly improve the risk
profile of patients with ESRD. Alternate dialysis strategies
that reduce the impact of dramatic fluid and electrolyte shifts
and other novel therapies tailored to the unique risk profile
of at-risk ESKD patients identified in this study should be
developed and tested.
MATERIALS AND METHODS
Patient population and data source
We examined patient data from patients who underwent long-term
hemodialysis treatment from 1 January 2002 to 1 January 2005 in
565 outpatient dialysis clinics of a large dialysis organization in the
United States (DaVita; formerly Gambro Healthcare). These data,
which have been described previously,3 include information on
demographic characteristics, laboratory parameters, medication use,
treatment- to treatment-specific dialysis care, and clinical outcomes,
including occurrence of adverse events within hemodialysis facilities.
Using this resource, we had access to the records of more than
43,000 hemodialysis patients dialyzed over the 4-year study period.
Study design
We used a case–control study design to compare in-clinic SCA
patients (defined as patients who experienced an SCA within the
facility of the outpatient hemodialysis clinic) with selected matched
controls. The methods we used to identify and adjudicate the SCA
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cohort and the detailed clinical information available for each
patient from electronic charts have been published previously.3,12
Using an existing database of all adverse events occurring within the
dialysis clinic facility, we identified a cohort of SCA patients by
individual event narrative review and adjudication of qualifying
events by three study physicians. We excluded patients from the SCA
cohort who had missing data regarding age, date of first
hemodialysis in accordance with our control selection strategy.
Because our primary purpose was to examine the influence of
dialysis factors on SCA, we further limited the case cohort to only
patients who had been receiving outpatient dialysis for at least 90
days before SCA to allow for sufficient lead time for examination of
the factors relating to the dialysis prescription and practice before
the event. The overall SCA rate was very similar to other published
event rates of in-clinic SCA.8,45
We used a frequency-matching strategy46 to select controls
randomly who did not experience an in-clinic adverse event during
the study period. Three controls were selected for every case patient
from the entire population of available subjects (approximately
43,000 subjects). Frequency matching allows for random selection of
a control cohort that has a similar distribution for selected variables
as the case population. To reduce the influence of nonmodifiable
demographic factors on our analysis, the following matching criteria
were used, each measured at the time of the SCA event: age, dialysis
vintage (number of years receiving hemodialysis), and year of
treatment. Controls were assigned an ‘index date’ corresponding to
the SCA event date recorded for case patients to allow for matching
by these variables.
Clinical demographic and comorbid characteristics
Detailed clinical and laboratory data were obtained from the
clinical database. Variables used for the purpose of this analysis
were patient gender, age, race (black, white, Hispanic, and other,
as reported to DaVita), and years on dialysis. We recorded history
of preexisting medical conditions, using organ-based groupings
of International Classification of Diseases Clinical Modification
(ICD-9) codes recorded in the clinical database. The codes used to
define comorbid conditions were as follows: diabetes, 250.xx;
coronary artery disease, 410.xx–414.xx (ischemic heart disease),
and procedure code 36.11 (coronary bypass surgery); congestive
heart failure, 425.xx (cardiomyopathy) and 428.xx (heart failure);
arrhythmia, 427.xx (cardiac dysrhythmia), 426.xx (conduction
disorders), and procedure code 37.7 (pacemaker placement); other
cardiac disease, 402.xx (hypertensive heart disease) and 429.xx
(other heart disease); cerebrovascular disease (430.xx-438.xx);
peripheral vascular disease, 440.xx–449.xx, 459.9 (unspecified
circulatory system disorder), and procedure code 38.1 (endarter-
ectomy), hyperlipidemia (272.xx); hypertension, 401.xx–405.xx,
362.11 (hypertensive retinopathy), and 437.2 (hypertensive
encephalopathy). We supplemented this information with addi-
tional data on the comorbid conditions listed above and history
of tobacco smoking by linking the clinical database to data
available on the Medical Evidence Form 2728 of the United States
Renal Data System.
Blood samples were drawn by uniform techniques in all DaVita
clinics and measured by automated and standardized methods in a
central laboratory. Most laboratory values, including serum
albumin, creatinine, potassium, calcium, phosphorus, hemoglobin,
intact parathyroid hormone, urea nitrogen levels, were measured at
least monthly, and data from 90 days before the event or index date
were available for review.
Medication use
From medication data contained in the clinical database, we
determined if calcium channel blockers, ACEI/ARBs, b-blockers,
aspirin, HMG Co-A reductase inhibitors (statins), and other
antiarrhythmic medications had been prescribed to patients before
or at the time of the event by comparing medications recorded in
the clinical database to a list of known generic and brand names.
Dialysis-specific data
Dialysis-specific data were included in the treatment information
collected during the 90-day period preceding the index/event date.
These data included composition of the dialysate (potassium and
calcium concentration) that was prescribed on the day of the CA
event or index date. Other parameters included intradialytic
ultrafiltration volume, expressed as percentage of post-dialysis
weight removed during the course of treatment, and dialysis
medications administered to patients. To reduce the effect of
intrapersonal variability over shorter periods, we also examined
4-week averaged ultrafiltration volume and mean dialysate electro-
lyte concentrations.
Statistical analysis
Baseline characteristics were compared using the Wilcoxon’s rank-
sum test for continuous variables and the Pearson w2-test for
categorical variables. All continuous variables are described as
medians with 25th and 75th percentiles unless otherwise specified.
Categorical variables are expressed as percentages.
A multivariable logistic regression model was developed to
evaluate factors that were associated with SCA. Variables examined
for possible inclusion in the model were selected by one of three
criteria: statistical strength of association with the outcome
(unadjusted association, Po0.1), prior studies,8,9 and clinical
insight regarding factors likely to contribute to adverse outcomes.
Restricted cubic spline transformations were applied to continuous
measures and the univariable association of the transformed variable
with SCD was compared with a linear association using logistic
models. When the linearity assumptions were violated, variables
were transformed as appropriate. Internal validation was performed
using bootstrapping to calculate a bias-corrected measure of model
performance.47
All tests were two sided and were carried out using SAS 8.2
(SAS Institute, Cary, NC). Results were declared significant at a
P-value of o0.05.
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